AC Immune Reports Second Quarter 2018 Financial Results and Corporate Update

• New total cash position of approximately CHF 210 million that is expected to extend cash runway to Q3 2021, excluding potential incoming milestones
• Financial position strengthened after Q2 close due to issuance of new shares, raising gross proceeds of USD 117.5 million
• Crenezumab: Phase 3 trial CREAD 2 fully recruited in July 2018; new Phase 2 data analysis provides strong evidence for principal target engagement of Abeta oligomers
• Selection of small molecules targeting Tau (Tau Morphomers^TM) for clinical development in Alzheimer's disease

AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced financial results for the second quarter and first half ended June 30, 2018.

Read the full media release below.